Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Rund 40 Mio. USD Staatsaufträge bis Juni 2029 gebucht: Jetzt zählt die Marge!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Contract Pharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
MimAbxience, OncoPrecision Agree to Advance Lead ADC Candidate
MiFDA Approves GSK Treatment for ALK-Positive NSCLC
MiShionogi Closes $2B IntraBio Deal, Adds Rare Disease Drug AQNEURSA
MiLotte Biologics Marks Completion of Songdo Bio Campus Plant 1
MiThermo Fisher Launches New Medium for Adenovirus Vaccine Production
MiGeneDx Taps Everett Cunningham as CEO
MiPfizer Bets $330M on Starna's In Vivo CAR-T Programs for Autoimmune Diseases
DiMade Scientific, Orca Bio Reach Long-Term Pact for Tregzi Manufacturing
DiOXB, Aura to Partner on Phase III Development, Future Supply of Oncology Candidate
DiTreeFrog Therapeutics Appoints James Sterling as CFO
DiLotte Biologics Agrees to Major Manufacturing Deal with Global Pharma Company
DiGene2Cure, Viralgen Partner to Advance Gene Therapies for Rare Pediatric Diseases
DiQosina Launches Redesigned Website
DiGilead Inks Deals with Dr. Reddy's, Eva Pharma, Ferozsons to Expand Ebola BVD Treatment
Diargenx Expands Cradle AI Platform for Antibody Discovery
DiKörber Launches Integrated Pharma Packaging Line for Vials and Syringes
DiThree Developers Tap AGC Biologics' New Yokohama Cell Therapy Site
Di10x Genomics Expands Autoimmune Diagnostics Research Through Global Partnerships
MoCorePharma Adds Spray Drying Platform for Poorly Soluble APIs
MoBiocon's Pebrilzo, A Perjeta Biosimilar, Approved by FDA for HER2+ Breast Cancer
MoAmyriAD Acquires ADvantage Alzheimer's Program, Boosting Clinical-Stage Pipeline
MoBiomapas Enters US Market with Acquisition of Alira Health's CMC Business
MoBiogen, Trimtech Partner on Neurodegenerative Disease Degraders
MoJ&J to Acquire Ollin Biosciences in $2.2B Ophthalmology Deal
MoAptamer Names James McNamara Head of Oligonucleotide Therapeutic Development